10-K Filing

ARROWHEAD PHARMACEUTICALS, INC. CIK: 879407 FY 2020

Filing Information

Form Type	10-K
Accession Number	`0001564590-20-054893`
Period End Date	20200930
Filing Date	20201123
Fiscal Year	2020
Fiscal Period	FY
XBRL Instance	arwr-10k_20200930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 70 Income Statement 83 Cash Flow Statement 83 Stockholders Equity 35

Balance Sheet 70 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	102.38M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	95.51M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$221.80M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$143.58M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	102.38M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$661.36K	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$845.67K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	95.51M	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$4.25M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$3.32M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.78M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$2.56M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$85.02M	USD	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$36.90M	USD	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$86.89M	USD	Point-in-time
TOTAL CURRENT ASSETS	`AssetsCurrent`	$322.37M	USD	Point-in-time
TOTAL CURRENT ASSETS	`AssetsCurrent`	$265.25M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$23.21M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$30.88M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$17.06M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$15.36M	USD	Point-in-time
Long term investments	`HeldToMaturitySecuritiesNoncurrent`	$44.18M	USD	Point-in-time
Long term investments	`HeldToMaturitySecuritiesNoncurrent`	$137.49M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$16.14M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$144.15K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$265.36K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$349.85M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$522.50M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$6.83M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$7.65M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$6.50M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$5.39M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$8.06M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$4.96M	USD	Point-in-time
Lease liabilities	`OperatingLeaseLiabilityCurrent`	$1.09M	USD	Point-in-time
Deferred rent	`DeferredRentCreditCurrent`	$173.95K	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$19.29M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$77.77M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$16.56K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$17.26K	USD	Point-in-time
TOTAL CURRENT LIABILITIES	`LiabilitiesCurrent`	$40.68M	USD	Point-in-time
TOTAL CURRENT LIABILITIES	`LiabilitiesCurrent`	$97.07M	USD	Point-in-time
Lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$20.04M	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$3.70M	USD	Point-in-time
Deferred revenue, net of current portion	`ContractWithCustomerLiabilityNoncurrent`	$5.04M	USD	Point-in-time
TOTAL LONG-TERM LIABILITIES	`LiabilitiesNoncurrent`	$20.04M	USD	Point-in-time
TOTAL LONG-TERM LIABILITIES	`LiabilitiesNoncurrent`	$8.74M	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 145,000,000 shares authorized; 102,376,303 and 95,506,271 shares issued and outstanding as of September 30, 2020 and September 30, 2019, respectively	`CommonStockValue`	$187.88K	USD	Point-in-time
Common stock, $0.001 par value; 145,000,000 shares authorized; 102,376,303 and 95,506,271 shares issued and outstanding as of September 30, 2020 and September 30, 2019, respectively	`CommonStockValue`	$194.75K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$965.41M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$664.09M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$18.43K	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-391.62K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-503.84M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-419.29M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$244.59M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$461.78M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-555.19K	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$95.24M	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$244.04M	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$80.87M	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$461.78M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$349.85M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$522.50M	USD	Point-in-time

Income Statement 83 line items

Line Item	Tag	Value	Unit	Period
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$168.80M	USD	Annual
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$16.14M	USD	Annual
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$7.63M	USD	1 Quarter
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$27.38M	USD	1 Quarter
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$42.70M	USD	1 Quarter
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$23.53M	USD	1 Quarter
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$48.15M	USD	1 Quarter
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$87.99M	USD	Annual
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$43.29M	USD	1 Quarter
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$34.66M	USD	1 Quarter
REVENUE	`RevenueFromContractWithCustomerExcludingAssessedTax`	$29.45M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$52.97M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$128.87M	USD	Annual
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$81.05M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$26.56M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$19.11M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$52.28M	USD	Annual
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$107.60M	USD	Annual
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$72.08M	USD	Annual
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$181.15M	USD	Annual
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$-4.85M	USD	1 Quarter
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$61.19M	USD	Annual
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$-22.24M	USD	1 Quarter
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$9.64M	USD	1 Quarter
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$22.01M	USD	1 Quarter
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$10.95M	USD	1 Quarter
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$18.60M	USD	1 Quarter
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$-15.95M	USD	1 Quarter
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$-93.16M	USD	Annual
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$-50.12M	USD	1 Quarter
OPERATING INCOME (LOSS)	`OperatingIncomeLoss`	$-55.94M	USD	Annual
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$1.05M	USD	Annual
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$6.96M	USD	Annual
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$9.19M	USD	Annual
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$432.14K	USD	Annual
Other Income (expense)	`OtherNonoperatingIncomeExpense`	$7.49K	USD	Annual
Other Income (expense)	`OtherNonoperatingIncomeExpense`	$-582.52K	USD	Annual
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$6.96M	USD	Annual
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$1.49M	USD	Annual
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$8.61M	USD	Annual
INCOME (LOSS) BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-54.45M	USD	Annual
INCOME (LOSS) BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-84.55M	USD	Annual
INCOME (LOSS) BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$68.15M	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$173.55K	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$2.40K	USD	Annual
Provision for income taxes	`IncomeTaxExpenseBenefit`	$2.40K	USD	Annual
NET INCOME (LOSS)	`NetIncomeLoss`	$-84.55M	USD	Annual
NET INCOME (LOSS)	`NetIncomeLoss`	$67.97M	USD	Annual
NET INCOME (LOSS)	`NetIncomeLoss`	$-54.45M	USD	Annual
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$0.12	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$0.21	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$0.25	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$0.13	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$-0.65	USD	Annual
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$-0.84	USD	Annual
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$-0.48	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$0.72	USD	Annual
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$-0.13	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$-0.03	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - BASIC	`EarningsPerShareBasic`	$-0.20	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$-0.65	USD	Annual
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$0.13	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$0.12	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$0.69	USD	Annual
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$0.24	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$-0.48	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$0.21	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$-0.03	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$-0.13	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$-0.20	USD	1 Quarter
NET INCOME (LOSS) PER SHARE - DILUTED	`EarningsPerShareDiluted`	$-0.84	USD	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	100.72M	shares	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	83.64M	shares	Annual
Weighted average shares outstanding - basic	`WeightedAverageNumberOfSharesOutstandingBasic`	93.86M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	83.64M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	98.61M	shares	Annual
Weighted average shares outstanding - diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	100.72M	shares	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$410.06K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-54.80K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-370.06K	USD	Annual
COMPREHENSIVE INCOME (LOSS)	`ComprehensiveIncomeNetOfTax`	$67.60M	USD	Annual
COMPREHENSIVE INCOME (LOSS)	`ComprehensiveIncomeNetOfTax`	$-54.51M	USD	Annual
COMPREHENSIVE INCOME (LOSS)	`ComprehensiveIncomeNetOfTax`	$-84.14M	USD	Annual

Cash Flow Statement 83 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-19.84M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-13.61M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$67.97M	USD	Annual
Net income (loss)	`ProfitLoss`	$-84.55M	USD	Annual
Net income (loss)	`ProfitLoss`	$23.90M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$20.34M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$11.70M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-54.45M	USD	Annual
Net income (loss)	`ProfitLoss`	$-48.43M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$12.04M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-2.67M	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$432.14K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$12.39M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$8.45M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$43.38M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$4.70M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$4.44M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$5.94M	USD	Annual
Amortization/(accretion) of note premiums	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-525.30K	USD	Annual
Amortization/(accretion) of note premiums	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-1.07M	USD	Annual
Amortization/(accretion) of note premiums	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-383.07K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$333.99K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$259.58K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$184.31K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$3.71M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-319.17K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$387.46K	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-5.27M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-63.51M	USD	Annual
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$82.80M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-821.01K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$4.84M	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-1.27M	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$2.45M	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$1.02M	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$1.99M	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$1.10M	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$2.23M	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$-414.29K	USD	Annual
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivities`	$-95.39M	USD	Annual
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivities`	$-47.22M	USD	Annual
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivities`	$173.03M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$11.95M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.42M	USD	Annual
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$12.00M	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$278.96M	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$52.08M	USD	Annual
Purchases of investments	`PaymentsToAcquireInvestments`	$90.27M	USD	Annual
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$54.52M	USD	Annual
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$50.14M	USD	Annual
Proceeds from sale of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$46.07M	USD	Annual
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivities`	$-47.75M	USD	Annual
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivities`	$-7.43M	USD	Annual
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivities`	$-240.78M	USD	Annual
Principal payments on notes payable	`RepaymentsOfNotesPayable`	$2.42M	USD	Annual
Principal payments on notes payable	`RepaymentsOfNotesPayable`	$208.51K	USD	Annual
Payment of taxes for net share settled restricted stock unit issuances	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$54.67K	USD	Annual
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$8.28M	USD	Annual
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$3.63M	USD	Annual
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$7.47M	USD	Annual
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$250.48M	USD	Annual
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$56.59M	USD	Annual
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$250.50M	USD	Point-in-time
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$60.52M	USD	Annual
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivities`	$257.95M	USD	Annual
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivities`	$66.38M	USD	Annual
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivities`	$59.95M	USD	Annual
NET INCREASE (DECREASE) IN CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$191.67M	USD	Annual
NET INCREASE (DECREASE) IN CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-78.22M	USD	Annual
NET INCREASE (DECREASE) IN CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$5.29M	USD	Annual
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$30.13M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$24.84M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$221.80M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$143.58M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$30.13M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$24.84M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$221.80M	USD	Point-in-time
CASH AND CASH EQUIVALENTS AT END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$143.58M	USD	Point-in-time
Interest paid	`InterestPaidNet`	$27.44K	USD	Annual
Interest paid	`InterestPaidNet`	$173.38K	USD	Annual
Income Taxes (Paid) Refunded	`IncomeTaxesPaidNet`	$-2.40K	USD	Annual
Income Taxes (Paid) Refunded	`IncomeTaxesPaidNet`	$103.44K	USD	Annual
Income Taxes (Paid) Refunded	`IncomeTaxesPaidNet`	$-302.40K	USD	Annual

Stockholders Equity 35 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$95.24M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$244.04M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$80.87M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$461.78M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$43.38M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$12.39M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$8.45M	USD	Annual
Exercise of stock options, Amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$7.47M	USD	Annual
Exercise of stock options, Amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.66M	USD	Annual
Exercise of stock options, Amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$8.28M	USD	Annual
Exercise of stock options, Shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	1.11M	shares	Annual
Exercise of warrants, Amount	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$1.24M	USD	Annual
Common stock - restricted stock units vesting, Amount	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	$-54.67K	USD	Annual
Common stock - issued for cash, Amount	`StockIssuedDuringPeriodValueNewIssues`	$250.48M	USD	Annual
Common stock - issued for cash, Amount	`StockIssuedDuringPeriodValueNewIssues`	$60.52M	USD	Annual
Common stock - issued for cash, Amount	`StockIssuedDuringPeriodValueNewIssues`	$56.59M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$410.06K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-54.80K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-370.06K	USD	Annual
Deconsolidation of Ablaris Therapeutics, Inc.	`NoncontrollingInterestDecreaseFromDeconsolidation`	$555.19K	USD	Annual
Net income (loss)	`ProfitLoss`	$-19.84M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-13.61M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$67.97M	USD	Annual
Net income (loss)	`ProfitLoss`	$-84.55M	USD	Annual
Net income (loss)	`ProfitLoss`	$23.90M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$20.34M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$11.70M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-54.45M	USD	Annual
Net income (loss)	`ProfitLoss`	$-48.43M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$12.04M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-2.67M	USD	1 Quarter
Ending Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$95.24M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$244.04M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$80.87M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$461.78M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.